Newton Jessica R, Miao Yubin, Deutscher Susan L, Quinn Thomas P
Department of Biochemistry, University of Missouri, Columbia, Missouri, USA.
J Nucl Med. 2007 Mar;48(3):429-36.
Random bacteriophage (phage) display peptide libraries have traditionally been used for the selection of clones that bind specific tissues, tumors, and antigens. However, once the targeting peptide is synthetically produced, it often displays a lower affinity than the original phage because of a lack of avidity effects and removal from the virion surface. We hypothesized that multivalent bifunctional phage displaying peptides that target novel molecular biomarkers would facilitate the in vivo imaging of cancer. This study provides proof of principle for the use of phage displaying multiple melanocortin-1 receptor-homing peptides for the pretargeting and subsequent imaging of murine melanomas in vivo.
A 2-step melanoma pretargeting-imaging system was developed by first generating and biotinylating phage that displayed up to 5 copies of alpha-melanocyte-stimulating hormone (alpha-MSH) peptide analogs. Second, streptavidin was conjugated to diethylenetriaminepentaacetic acid for the purpose of radiolabeling with (111)In.
The specificity of the MSH2.0 phage for the B16-F1 melanoma was demonstrated both in vitro and in vivo. In vitro micropanning assays with phage at inputs of 10(7) and 10(6) transducing units per milliliter resulted in approximately 200- and approximately 1,000-fold-greater recovery of the MSH2.0 phage over the background, respectively. In vivo distribution studies indicated that melanoma uptake values were 2.6 +/- 1.1, 0.6 +/- 0.2, and 1.0 +/- 0.1 (mean +/- SD) percentage injected dose per gram at 0.5, 6, and 24 h after the injection of (111)In-radiolabeled streptavidin ((111)In-SA). The accumulation of radioactivity within the tumor was 1.8 times greater for the biotinylated MSH2.0 phage than for the biotinylated wild-type phage. These data, combined with reduction by 2.4-fold through competition with a nonradiolabeled alpha-MSH peptide analog, indicated the specific targeting of melanoma tumors in vivo. SPECT/CT image analysis of B16-F1 melanoma-bearing mice showed that intravenously injected biotinylated alpha-MSH phage were retained within melanoma tumors at 4 h after injection of (111)In-SA.
This study demonstrated the use of multivalent bifunctional phage in a 2-step pretargeting-imaging system.
传统上,随机噬菌体(噬菌体)展示肽库用于筛选能结合特定组织、肿瘤和抗原的克隆。然而,一旦靶向肽通过合成生产,由于缺乏亲合力效应以及从病毒体表面去除,其亲和力通常低于原始噬菌体。我们推测,展示靶向新型分子生物标志物的肽的多价双功能噬菌体将有助于癌症的体内成像。本研究为使用展示多种促黑素细胞激素-1受体归巢肽的噬菌体进行小鼠黑色素瘤的预靶向和后续体内成像提供了原理证明。
开发了一种两步黑色素瘤预靶向成像系统,首先生成并生物素化展示多达5个α-促黑素细胞激素(α-MSH)肽类似物拷贝的噬菌体。其次,将链霉亲和素与二乙烯三胺五乙酸缀合,以便用(111)铟进行放射性标记。
MSH2.0噬菌体对B16-F1黑色素瘤的特异性在体外和体内均得到证实。在体外微淘选试验中,每毫升输入10(7)和10(6)个转导单位的噬菌体,MSH2.0噬菌体的回收率分别比背景高约200倍和约1000倍。体内分布研究表明,在注射(111)铟标记的链霉亲和素((111)In-SA)后0.5、6和24小时,黑色素瘤的摄取值分别为每克注射剂量的2.6±1.1、0.6±0.2和1.0±0.1(平均值±标准差)百分比。生物素化的MSH2.0噬菌体在肿瘤内的放射性积累比生物素化的野生型噬菌体高1.8倍。这些数据,再加上通过与未标记的α-MSH肽类似物竞争而降低2.4倍,表明噬菌体在体内对黑色素瘤肿瘤具有特异性靶向作用。对携带B16-F1黑色素瘤的小鼠进行SPECT/CT图像分析表明,在注射(111)In-SA后4小时,静脉注射的生物素化α-MSH噬菌体保留在黑色素瘤肿瘤内。
本研究证明了多价双功能噬菌体在两步预靶向成像系统中的应用。